1
|
SakallioĞlu AK, Kaya S, Garİp R, Güçlü H. COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN. Retina 2024; 44:1196-1202. [PMID: 38437826 DOI: 10.1097/iae.0000000000004085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2024]
Abstract
PURPOSE To compare topical nonsteroidal anti-inflammatory drug (NSAID) efficacy on intravitreal injection-induced pain reduction and determine the most efficient topical NSAID. METHODS This randomized-controlled study included 662 eyes of 662 patients. Based on the types of NSAID administered before intravitreal injection, eight subgroups were formed. In the control group, a sterile saline solution was applied instead of NSAIDs. The visual analog scale was used to assess pain scores after intravitreal injection. The visual analog scale scores were noted immediately and 6 hours following injection (sixth hour). RESULTS Nepafenac 0.3%, nepafenac 0.1%, and bromfenac 0.09% had the lowest scores, immediately after and after 6 hours, with no significant differences. Diclofenac and ketorolac had higher visual analog scale scores than the first trio but lower scores than the control group. Flurbiprofen, pranoprofen, and indomethacin did not significantly affect immediate pain; however, at the sixth hour, the visual analog scale scores were significantly reduced. CONCLUSION Nepafenac 0.3%, nepafenac 0.1%, and bromfenac 0.09% were the most effective NSAIDs for pain reduction. Although some NSAIDs did not have a significant effect on immediate pain, they all provided significant benefits at the sixth hour.
Collapse
Affiliation(s)
| | | | - Rüveyde Garİp
- Trakya University School of Medicine, Department of Ophthalmology, Edirne, Turkey; and
| | - Hande Güçlü
- Trakya University School of Medicine, Department of Ophthalmology, Edirne, Turkey; and
| |
Collapse
|
2
|
Mehanna CJ, Souied E, Coscas F, Razavi S, Cohen SY. [Update on practice of intravitreal injections. Recommendations of the Fédération France Macula, the Société française de la rétine, and the Club francophone des spécialistes de la rétine]. J Fr Ophtalmol 2023; 46:956-960. [PMID: 37120345 DOI: 10.1016/j.jfo.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 03/16/2023] [Indexed: 05/01/2023]
Affiliation(s)
- C-J Mehanna
- Centre hospitalier intercommunal de Créteil, 94000 Créteil, France
| | - E Souied
- Centre hospitalier intercommunal de Créteil, 94000 Créteil, France; Fédération France Macula, CHIC, 94000 Créteil, France
| | - F Coscas
- Société française de la rétine, 113, boulevard Saint-Germain, 75006 Paris, France
| | - S Razavi
- Club francophone des spécialistes de la rétine, 2, rue Ambroise-Paré, 75010 Paris, France
| | - S-Y Cohen
- Centre hospitalier intercommunal de Créteil, 94000 Créteil, France; Centre ophtalmologique d'imagerie et de laser, 11, rue Antoine-Bourdelle, 75015 Paris, France.
| |
Collapse
|
3
|
Seyyar S, Mete A, Tıskaoğlu N. Evaluation of YouTube videos as a patient information source on intravitreal injection procedures. J Fr Ophtalmol 2022; 45:748-755. [DOI: 10.1016/j.jfo.2022.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 02/14/2022] [Accepted: 02/14/2022] [Indexed: 12/01/2022]
|
4
|
Lee DH, Kim M, Choi EY, Chin HS, Kim M. Efficacy of Pretreatment with Preservative-Free Topical Bromfenac in Improving Post-Intravitreal-Injection Pain: A Prospective Pilot Study. J Clin Med 2022; 11:jcm11144172. [PMID: 35887936 PMCID: PMC9319687 DOI: 10.3390/jcm11144172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 07/06/2022] [Accepted: 07/14/2022] [Indexed: 11/24/2022] Open
Abstract
(1) Background: To determine the analgesic effect of pretreatment topical bromfenac instillation in patients undergoing intravitreal anti-VEGF treatment. (2) Methods: A prospective, non-randomized pilot study was conducted in patients scheduled to receive repeated intravitreal anti-VEGF injections at a single tertiary hospital. Before the planned second injection, the patients received topical bromfenac eye drops twice a day for 3 days. At 1, 6, and 24 h after the first and second injections, the post-injection pain scores were determined using the numerical rating scale (NRS) telephonically. (3) Results: A total of 28 patients were enrolled in this study. After the first intravitreal injection, the NRS pain scores were 4.04 ± 1.90 at 1 h, 1.57 ± 1.75 at 6 h, and 0.93 ± 1.27 at 24 h. The pain scores after the second intravitreal injection significantly decreased at each measurement time point (p = 0.002, 0.055, and 0.004, respectively) compared to the first injection. (4) Conclusions: The use of topical bromfenac eye drops before intravitreal injection can lead to a significant improvement in injection-related pain scores, which is the basis for a future large-scale randomized comparative study.
Collapse
Affiliation(s)
- Dong-Hyun Lee
- Department of Ophthalmology, Inha University School of Medicine, Incheon 22332, Korea; (D.-H.L.); (H.-S.C.)
- Inha Vision Science Laboratory, Inha University School of Medicine, Incheon 22332, Korea
- Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea; (M.K.); (E.-Y.C.)
| | - Minha Kim
- Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea; (M.K.); (E.-Y.C.)
| | - Eun-Young Choi
- Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea; (M.K.); (E.-Y.C.)
| | - Hee-Seung Chin
- Department of Ophthalmology, Inha University School of Medicine, Incheon 22332, Korea; (D.-H.L.); (H.-S.C.)
- Inha Vision Science Laboratory, Inha University School of Medicine, Incheon 22332, Korea
| | - Min Kim
- Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea; (M.K.); (E.-Y.C.)
- Correspondence: ; Tel.: +82-2-2019-3440
| |
Collapse
|
5
|
Nuzbrokh Y, Kassotis AS, Ragi SD, Jauregui R, Tsang SH. Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. Ophthalmol Ther 2020; 9:709-724. [PMID: 32740739 PMCID: PMC7708583 DOI: 10.1007/s40123-020-00287-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Indexed: 12/24/2022] Open
Abstract
Patient safety is a primary priority in the conduction of retinal gene therapy trials. An understanding of risk factors and mitigation strategies for post-procedure complications is crucial for the optimization of gene therapy clinical trial protocols. In this review, we synthesize the literature on ocular delivery methods, vector platforms, and treatment-emergent adverse effects in recent gene therapy clinical trials for inherited retinal diseases.
Collapse
Affiliation(s)
- Yan Nuzbrokh
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA
- Jonas Children's Vision Care, New York, NY, USA
- Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Alexis S Kassotis
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA
| | - Sara D Ragi
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA
- Jonas Children's Vision Care, New York, NY, USA
| | - Ruben Jauregui
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA
- Jonas Children's Vision Care, New York, NY, USA
| | - Stephen H Tsang
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA.
- Jonas Children's Vision Care, New York, NY, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
| |
Collapse
|
6
|
Ramos MS, Xu LT, Singuri S, Castillo Tafur JC, Arepalli S, Ehlers JP, Kaiser PK, Singh RP, Rachitskaya AV, Srivastava SK, Sears JE, Schachat AP, Babiuch AS, Sharma S, Martin DF, Lowder CY, Singh AD, Yuan A, Nowacki AS. Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors. Ophthalmol Retina 2020; 5:625-632. [PMID: 33059077 PMCID: PMC7548755 DOI: 10.1016/j.oret.2020.09.024] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/17/2020] [Accepted: 09/29/2020] [Indexed: 12/27/2022]
Abstract
Purpose The intravitreal injection (IVI) of pharmacologic agents is the most commonly performed ocular procedure and is associated with a host of complications. Most IVI-related complications data are derived from randomized controlled clinical trials, which report a high adverse event rate. The nature of these protocol-driven trials limit their applicability to the diverse circumstances seen in routine clinical practice. The goal of this study was to determine the prevalence of patient-reported IVI-related complications, their risk factors, and the manner in which patients sought treatment at a tertiary eye care center. Design Retrospective, institutional review board–approved study. Participants Forty-four thousand seven hundred thirty-four injections in 5318 unique patients at the Cleveland Clinic Cole Eye Institute from 2012 through 2016. Methods Intravitreal injection. Main Outcome Measures Complication occurrence within 15 days of injection. Results From 2012 through 2016, a total of 44734 injections were performed in 5318 unique patients. Overall, complication rates were low, representing 1.9% of all injections, with 1031 unique complications in 685 patients (12.9%). The most common minor complications, or those not requiring intervention, were irritation (n = 312) and subconjunctival hemorrhage (n = 284). The most common serious complications, or those requiring intervention, were corneal abrasion (n = 46) and iritis (n = 31). Most complications (66%) were managed adequately by a telephone or Epic (Epic Systems Corp., Verona, WI) electronic message encounter only. Importantly, no injection protocol parameter, such as type of anesthesia, preparation, or post-injection medication, increased the risk of a complication. However, a patient’s gender, age, number of previous injections, and provider strongly influenced the risk of patient-reported complications. Conclusions Overall, complication rates seen in routine clinical practice were low compared with clinical trial reporting. Providers should feel confident in the safety and administration of IVI during times when follow-up office visits and resources may be limited. When performing an IVI, factors such as a patient’s gender, age, number of previous injections, and provider must be taken into account to ensure the best possible outcomes.
Collapse
Affiliation(s)
- Michael S Ramos
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Lucy T Xu
- Emory Eye Center, Department of Ophthalmology, Emory University, Atlanta, Georgia
| | - Srinidhi Singuri
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | | | - Sruthi Arepalli
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Justis P Ehlers
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Peter K Kaiser
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Rishi P Singh
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | | | | | - Jonathan E Sears
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | | | - Amy S Babiuch
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Sumit Sharma
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Daniel F Martin
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Careen Y Lowder
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Arun D Singh
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Alex Yuan
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
| | - Amy S Nowacki
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio
| |
Collapse
|
7
|
Kaplan RI, Rosen RB, Gentile RC. Optimizing the Patient Experience and Satisfaction: The Role of Topical NSAIDs with Intravitreal Injections. ACTA ACUST UNITED AC 2020; 4:459-460. [DOI: 10.1016/j.oret.2020.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 03/03/2020] [Indexed: 11/30/2022]
|